Graig Suvannavejh
Stock Analyst at Mizuho
(4.52)
# 266
Out of 5,152 analysts
175
Total ratings
54.55%
Success rate
20.99%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $19 → $20 | $19.86 | +0.70% | 12 | Mar 5, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $135.24 | +84.86% | 2 | Feb 25, 2026 | |
| INSM Insmed | Maintains: Outperform | $211 → $204 | $142.94 | +42.72% | 13 | Feb 24, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $5.23 | +91.20% | 1 | Feb 19, 2026 | |
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $8.60 | +62.79% | 1 | Feb 9, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $15.16 | -67.02% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $42.85 | +26.02% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $171.11 | +13.38% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $28.00 | +64.29% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $74.13 | +34.90% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $9.91 | +132.09% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $67.23 | -16.70% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $32.70 | +40.67% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $159.54 | +26.61% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.54 | +159.74% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.26 | +11,438.46% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.98 | +76.77% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.97 | +68.35% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.92 | +103.25% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $15.66 | -29.76% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.67 | +65.98% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.03 | -42.98% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.42 | +1.79% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.51 | +403.31% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.89 | +837.90% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.78 | -64.03% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $90.39 | -61.28% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $24.12 | -66.83% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $60.50 | -5.79% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $28.73 | -82.60% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.53 | +222.89% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.01 | +179.72% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $27.52 | +12.65% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $14.53 | +2,515.28% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.58 | +200.63% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $23.56 | +52.80% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.69 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $3.16 | +1,070.89% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $181.00 | -29.28% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Mar 5, 2026
Maintains: Neutral
Price Target: $19 → $20
Current: $19.86
Upside: +0.70%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $135.24
Upside: +84.86%
Insmed
Feb 24, 2026
Maintains: Outperform
Price Target: $211 → $204
Current: $142.94
Upside: +42.72%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $5.23
Upside: +91.20%
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $8.60
Upside: +62.79%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $15.16
Upside: -67.02%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $42.85
Upside: +26.02%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $171.11
Upside: +13.38%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $28.00
Upside: +64.29%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $74.13
Upside: +34.90%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.91
Upside: +132.09%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $67.23
Upside: -16.70%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $32.70
Upside: +40.67%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $159.54
Upside: +26.61%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.54
Upside: +159.74%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.26
Upside: +11,438.46%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.98
Upside: +76.77%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.97
Upside: +68.35%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.92
Upside: +103.25%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $15.66
Upside: -29.76%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $15.67
Upside: +65.98%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.03
Upside: -42.98%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.42
Upside: +1.79%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.51
Upside: +403.31%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.89
Upside: +837.90%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.78
Upside: -64.03%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $90.39
Upside: -61.28%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $24.12
Upside: -66.83%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $60.50
Upside: -5.79%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $28.73
Upside: -82.60%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.53
Upside: +222.89%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.01
Upside: +179.72%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $27.52
Upside: +12.65%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $14.53
Upside: +2,515.28%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.58
Upside: +200.63%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $23.56
Upside: +52.80%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.69
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $3.16
Upside: +1,070.89%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $181.00
Upside: -29.28%